Reuters logo
8 months ago
BRIEF-EMA says patients treated with direct-acting antivirals for hepatitis C may be at risk of hepatitis B re-activation
December 2, 2016 / 3:07 PM / 8 months ago

BRIEF-EMA says patients treated with direct-acting antivirals for hepatitis C may be at risk of hepatitis B re-activation

1 Min Read

Dec 2 (Reuters) - European Medicines Agency (EMA):

* Patients treated with direct-acting antivirals for hepatitis C may be at risk of hepatitis B re-activation

* Has recommended that, before starting treatment, all hep-c patients be screened for hepatitis B virus

* Cases of return of previously inactive hep B infection have been reported in patients on direct-acting antivirals who were infected with hep B & C

* Although frequency of hep B re-activation appears low, EMA recommends warning be included in prescribing information for the medicines

* Reviewed data on liver cancer in patients on direct-acting antivirals & concluded further studies are needed before firm conclusions can be drawn Source text (bit.ly/2gQ2MWE)

0 : 0
  • narrow-browser-and-phone
  • medium-browser-and-portrait-tablet
  • landscape-tablet
  • medium-wide-browser
  • wide-browser-and-larger
  • medium-browser-and-landscape-tablet
  • medium-wide-browser-and-larger
  • above-phone
  • portrait-tablet-and-above
  • above-portrait-tablet
  • landscape-tablet-and-above
  • landscape-tablet-and-medium-wide-browser
  • portrait-tablet-and-below
  • landscape-tablet-and-below